APM

Aptorum Group Ltd. (APM) | Rumor.io

Aptorum Group

APM

Attention (50-day avg)0%

Attention rank (50-day avg)#3,206

Bullish sentiment (50-day avg)100%

Price to earnings ratio2.81

Market capitalization3.9M

Earnings per share-1.9

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-1.4M

Social

What share of all stock conversation is about APM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Jun 10

A merger involving Aptorum Group Limited ($APM) was reportedly false, with some suggesting it was a "pump and dump" scheme.
The company's stock price may be impacted by a potential merger or other factors, with some users calling it a "sell the news event".
Some users are bullish on the stock, with one claiming to have bought more shares and another predicting a "boooom!!!!" in the stock price.

Generated by AI

Sentiment

Of the messages about APM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	73.55% -11.32
Bearish	—	—	—	26.45% +11.32

Bullish· Aug 22

$APM has a strong correlation with gold, with its price movement averaging 2.5x the percentage change in gold.
The company is expected to report significant earnings growth in Q3, with a potential 9x increase in earnings compared to its peers in the junior gold producer segment.
$APM is expected to release positive drill results in Q4, which may lead to a longer mine life and increased fair value for the stock.

Bearish· Jun 10

A merger rumor circulating about Aptrum Group Limited ($APM) has been deemed false by some, with accusations of being a "pump and dump" scheme.
The company's plan to dilute shares as part of a merger has been met with criticism, with some describing it as the "worst stock in the entire market."
Aptrum Group Limited's stock has been heavily shorted, with some individuals suggesting that the company's executives have been working to tank the stock in order to facilitate a secret share deal.

Generated by AI

Topics

Of the messages about APM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	0%	74.1%
Technical Analysis	—	—	50%	19.79%
Analysts	—	—	50%	5.98%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0.13%

Announcements· Aug 21

Aptorum Group Limited ($APM) announced an all-stock merger agreement with DiamiR Biosciences, adding a diagnostic laboratory business to its portfolio.
DiamiR Biosciences' APOE Genotyping Test received approval from the New York State Department of Health, enabling its use in blood, saliva, and tissue samples for Alzheimer's disease risk assessment.
The approval is expected to drive growth in the diagnostics market, which is projected to reach $9.22 billion in 2025, with massive potential for breakthroughs in Alzheimer's therapeutics.

Technical Analysis· Aug 22

The author believes $APM will experience a bullish run, potentially reaching $10 by tomorrow, and notes that the stock has bounced off its VWAP twice.
The author highlights the importance of the stock's trend line and notes that it has held the line, with a key level of support at $3.10-$3.15.
The author notes that the stock's charts do not lie, with a lower level of confirmation at $2.55 and an upside level at $2.94, and warns that if the stock drops below $2.55, it may experience further downward movement.

Generated by AI

Community

Of the messages about APM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	11.94%	51.69%
Newcomers	100%	100%	88.06%	48.31%

Regulars· Aug 21

$APM is experiencing a strong surge, reaching a new high of $4.21, with a 200% increase in a single day, and traders are expecting a possible squeeze to continue with a target of $4.40.
The stock's recent performance is being attributed to the New York State approval for DiamiR Biosciences' APOE Genotyping Test, a product of Aptorum Group, which has the potential to increase the company's valuation and attract more investors.
Traders are advised to be cautious and trim their positions as the stock price can fluctuate rapidly due to the high volume of short selling and the stock's low float, with a support level at $3.7 and a potential entry point at $4.81.

Newcomers· Aug 27

A newcomer to the APM discussion is optimistic about Aptorum Group's market position, citing DiamiR's APOE test approval as a key factor, and suggests a long position at $1.80 with targets of $2.20 and $2.50.
This individual is focusing on the potential for Aptorum Group to rise following the approval of DiamiR's APOE test, a key development that has boosted the company's market position.
The newcomer is advising others to stay alert to market trends and merger news, suggesting that these are crucial factors to watch for in the future of Aptorum Group's stock.

Generated by AI

Post-Merger company, Niki BioSolutions, Inc., to Trade on Nasdaq Under Ticker “NIKI” Aptorum Group Announces 1-for-10 Reverse Share Split and Delaware Redomestication in Connection with the Merger The Merger is Expected to Close in July 2026 NEW YORK, NY, July 16, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited, a Cayman Islands exempted company with limited liability (NASDAQ: APM) ("Aptorum Group” or “Aptorum” or “Company”), a clinical stage biopharmaceutical company dedicated to addressing unme

2mo agoYahoo Finance

Aptorum Group and DiamiR Biosciences Announce Three Presentations at 2026 Alzheimer’s Association International Conference

NEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, July 08, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, and DiamiR Biosciences (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced upcoming presentations at the annual Alzheimer’s Association International Conference (AAIC), taking place at the Excel

2mo agoYahoo Finance

Also Discussed

Investors talking about APM also mention

#	Name	Attention
1	Tharimmune Inc.THAR	0%new
2	PTIX - Protagenic Therapeutics, Inc.	——
3	MODV - ModivCare Inc.	——
4	BSLK - Bolt Projects Holdings, Inc.	——
5	Jupiter Neurosciences Inc.JUNS	0%new
6	MINM - Minim, Inc.	——
7	KAVL - Kaival Brands Innovations Group, Inc.	——
8	Power & Digital Infrastructure Acquisition II Corp.XPDB	0%0
9	Barinthus Biotherapeutics plcBRNS	0%new
10	Nkgen Biotech Inc.NKGN	0%0

Aptorum Group Ltd.

Healthcare
Biotechnology

Aptorum Group Ltd. is a clinical stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs. It focuses primarily on oncology, including orphan oncology indications, infectious diseases, metabolic diseases, and women's health, through its Therapeutics segment, which develops drug molecules and diagnostic technologies. Key pipeline candidates include SACT-1, a repurposed drug in phase 1 trials for neuroblastoma and other cancers, and ALS-4, a small molecule in phase 1 for bacterial infections such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa. The company also advances preclinical programs like RPIDD for rapid pathogen diagnostics, SACT-COV19 for coronavirus, and others targeting bacterial infections and specific indications. Additionally, Aptorum Group Ltd. operates a Non-Therapeutics segment involving healthcare services and diagnostics. Founded in 2010 and headquartered in the United Kingdom, it plays a role in addressing critical gaps in biopharmaceutical innovation for challenging medical conditions.

Website

Location

116 Village Boulevard

Princeton, NJ, 08540

United States

Social

What share of all stock conversation is about APM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Jun 10

A merger involving Aptorum Group Limited ($APM) was reportedly false, with some suggesting it was a "pump and dump" scheme.
The company's stock price may be impacted by a potential merger or other factors, with some users calling it a "sell the news event".
Some users are bullish on the stock, with one claiming to have bought more shares and another predicting a "boooom!!!!" in the stock price.

Generated by AI

Sentiment

Of the messages about APM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	73.55% -11.32
Bearish	—	—	—	26.45% +11.32

Bullish· Aug 22

$APM has a strong correlation with gold, with its price movement averaging 2.5x the percentage change in gold.
The company is expected to report significant earnings growth in Q3, with a potential 9x increase in earnings compared to its peers in the junior gold producer segment.
$APM is expected to release positive drill results in Q4, which may lead to a longer mine life and increased fair value for the stock.

Bearish· Jun 10

A merger rumor circulating about Aptrum Group Limited ($APM) has been deemed false by some, with accusations of being a "pump and dump" scheme.
The company's plan to dilute shares as part of a merger has been met with criticism, with some describing it as the "worst stock in the entire market."
Aptrum Group Limited's stock has been heavily shorted, with some individuals suggesting that the company's executives have been working to tank the stock in order to facilitate a secret share deal.

Generated by AI

Topics

Of the messages about APM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	0%	74.1%
Technical Analysis	—	—	50%	19.79%
Analysts	—	—	50%	5.98%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0.13%

Announcements· Aug 21

Aptorum Group Limited ($APM) announced an all-stock merger agreement with DiamiR Biosciences, adding a diagnostic laboratory business to its portfolio.
DiamiR Biosciences' APOE Genotyping Test received approval from the New York State Department of Health, enabling its use in blood, saliva, and tissue samples for Alzheimer's disease risk assessment.
The approval is expected to drive growth in the diagnostics market, which is projected to reach $9.22 billion in 2025, with massive potential for breakthroughs in Alzheimer's therapeutics.

Technical Analysis· Aug 22

The author believes $APM will experience a bullish run, potentially reaching $10 by tomorrow, and notes that the stock has bounced off its VWAP twice.
The author highlights the importance of the stock's trend line and notes that it has held the line, with a key level of support at $3.10-$3.15.
The author notes that the stock's charts do not lie, with a lower level of confirmation at $2.55 and an upside level at $2.94, and warns that if the stock drops below $2.55, it may experience further downward movement.

Generated by AI

Community

Of the messages about APM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	11.94%	51.69%
Newcomers	100%	100%	88.06%	48.31%

Regulars· Aug 21

$APM is experiencing a strong surge, reaching a new high of $4.21, with a 200% increase in a single day, and traders are expecting a possible squeeze to continue with a target of $4.40.
The stock's recent performance is being attributed to the New York State approval for DiamiR Biosciences' APOE Genotyping Test, a product of Aptorum Group, which has the potential to increase the company's valuation and attract more investors.
Traders are advised to be cautious and trim their positions as the stock price can fluctuate rapidly due to the high volume of short selling and the stock's low float, with a support level at $3.7 and a potential entry point at $4.81.

Newcomers· Aug 27

A newcomer to the APM discussion is optimistic about Aptorum Group's market position, citing DiamiR's APOE test approval as a key factor, and suggests a long position at $1.80 with targets of $2.20 and $2.50.
This individual is focusing on the potential for Aptorum Group to rise following the approval of DiamiR's APOE test, a key development that has boosted the company's market position.
The newcomer is advising others to stay alert to market trends and merger news, suggesting that these are crucial factors to watch for in the future of Aptorum Group's stock.

Generated by AI

Aptorum Group

Social

Jun 10

Sentiment

Bullish· Aug 22

Bearish· Jun 10

Topics

Announcements· Aug 21

Technical Analysis· Aug 22

Community

Regulars· Aug 21

Newcomers· Aug 27

News

Aptorum Group plans 1-for-10 reverse split, merger closing

Aptorum Group Provides Update on DiamiR Biosciences Merger

Aptorum Group and DiamiR Biosciences Announce Three Presentations at 2026 Alzheimer’s Association International Conference

Also Discussed

Aptorum Group Ltd.

Company Information

Location

News

Aptorum Group plans 1-for-10 reverse split, merger closing

Aptorum Group Provides Update on DiamiR Biosciences Merger

Aptorum Group and DiamiR Biosciences Announce Three Presentations at 2026 Alzheimer’s Association International Conference

Also Discussed

Social

Jun 10

Sentiment

Bullish· Aug 22

Bearish· Jun 10

Topics

Announcements· Aug 21

Technical Analysis· Aug 22

Community

Regulars· Aug 21

Newcomers· Aug 27